Expression of microRNA-133a & microRNA-208b in Acute Myocardial Infarction

Status Completed

Clinical Trial Summary

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Clinical Trial Description

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05692752
Study type	Observational [Patient Registry]
Source	Islamia University of Bahawalpur
Contact
Status	Completed
Phase
Start date	December 28, 2022
Completion date	January 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05759078` - Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion	Phase 4
Recruiting	`NCT06038994` - Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
Recruiting	`NCT04968808` - Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)	N/A
Completed	`NCT03338504` - Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Recruiting	`NCT03317691` - The ALERT-Pilot Study	N/A
Active, not recruiting	`NCT05077683` - Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF	Phase 3
Recruiting	`NCT03957005` - Cardiovascular Risk Assessment Model in Patients With MI
Enrolling by invitation	`NCT05955950` - Gratitude Intervention in Promoting Self-care in Patients With Myocardial Infarction	N/A
Active, not recruiting	`NCT06141252` - Benefit of Hypothermia in OHCA Complicating AMI	N/A
Not yet recruiting	`NCT04560023` - Effectiveness of Multimedia Exposure in Patients Transferred to Hospital Suffering From Acute Myocardial Infarction	N/A
Recruiting	`NCT03809689` - Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET	N/A
Completed	`NCT05118009` - Artificial Intelligence Based Rapid Identification of ST-elevation Myocardial Infarction Using Electrocardiogram (ARISE)	N/A
Active, not recruiting	`NCT04753749` - Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy	N/A
Completed	`NCT04769219` - Secondary Prevention Education After Acute Myocardial Infarction	N/A
Active, not recruiting	`NCT05350969` - Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction	Phase 2
Recruiting	`NCT05999110` - Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR)	N/A
Completed	`NCT04167904` - Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction
Not yet recruiting	`NCT04989777` - IABP In AMI Patients With SCAI-B Study	N/A
Recruiting	`NCT05043610` - MSCs for Prevention of MI-induced HF	Phase 3
Recruiting	`NCT03600259` - Tianjin Inpatient Acute Myocardial Infarction Registry

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms